Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

Wall Street rallied on Monday, led by big gains in Nvidia, Palantir and other heavyweight AI-related companies following ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

Researchers are working on microscopic, wireless chips that can travel through the bloodstream and self-implant in a targeted ...

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

Lilly stock was up 4.8% at $969.14, putting it on pace for a record closing high, according to Dow Jones Market Data. The ...